AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25002194 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to asthma/COPD clinics
Number of subjects: 21361
Study 25002964 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation with Lactobacillus reuteri
Number of subjects: 61
Study 25003275 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-Minute Step Test (6MST)
Number of subjects: 32
Study 25003311 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery system; subjects received three mixed meals (1 g of carbohydrate/kg of body weight; 100 g maximum) with meal announcement and automated insulin dosing.
Number of subjects: 53
Study 25003359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days
Number of subjects: 23
Study 25003359 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 23
Study 25003359 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod (FTY720, Gilenya)
Number of subjects: 23
Study 25004134 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatients (FLU 002)
Number of subjects: 982
Study 25004134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatients (FLU 003)
Number of subjects: 982
Study 25004134 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU patients
Number of subjects: 982
Study 25004134 — intervention group
Group type: EXPERIMENTAL
Intervention: General ward patients
Number of subjects: 982
Study 25004340 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 165
Study 25004340 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-releasing intrauterine device
Number of subjects: 165
Study 25004404 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25-hydroxyvitamin D3 (25(OH)D3)
Number of subjects: 132
Study 25004404 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 3-epi-25-hydroxyvitamin D3 (3-epi-25(OH)D3)
Number of subjects: 132
Study 25004466 — intervention group
Group type: EXPERIMENTAL
Intervention: CoDuSe program (balance exercise program)
Number of subjects: 32
Study 25005255 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab with chemotherapy
Number of subjects: 0
Study 25005444 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin 0.4 μg/kg IV
Number of subjects: 14
Study 25005721 — intervention group
Group type: EXPERIMENTAL
Intervention: New or worsened diastolic dysfunction (DD) after CPB
Number of subjects: 109
Study 25005721 — intervention group
Group type: COMPARATOR
Intervention: Unchanged or improved diastolic dysfunction (DD) after CPB
Number of subjects: 109
Study 25005721 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 109
Study 25005721 — intervention group
Group type: EXPERIMENTAL
Intervention: Age ≥65 years
Number of subjects: 109
Study 25005721 — intervention group
Group type: EXPERIMENTAL
Intervention: New or worsened diastolic dysfunction (DD)
Number of subjects: 109
Study 25006228 — intervention group
Group type: EXPERIMENTAL
Intervention: UUI cohort
Number of subjects: 0
Study 25006228 — intervention group
Group type: COMPARATOR
Intervention: Non-UUI cohort
Number of subjects: 0
Study 25006744 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide association studies (GWAS) for emphysema patterns
Number of subjects: 9614
Study 25006744 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancer enrichment analysis for top GWAS associations
Number of subjects: 9614
Study 25006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Born outside the United States
Number of subjects: 2786
Study 25006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Born outside the United States and residing inside the United States
Number of subjects: 2786
Study 25006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Born outside the United States and residing outside the United States
Number of subjects: 2786
Study 25006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthplace in all continents
Number of subjects: 2786
Study 25006795 — intervention group
Group type: EXPERIMENTAL
Intervention: Latitude closer to the equator
Number of subjects: 2786
Study 25007130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 ([(14)C]-AZD8931) administered orally or intravenously; dosage not specified; single doses.
Number of subjects: 0
Study 25007130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in rats; specific metabolic pathways not detailed.
Number of subjects: 0
Study 25007130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in dogs; specific metabolic pathways not detailed.
Number of subjects: 0
Study 25007130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 metabolism in humans; specific metabolic pathways not detailed.
Number of subjects: 0
Study 25007130 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD8931 excretory profiles in humans; specific metabolites not detailed.
Number of subjects: 0
Study 25007364 — intervention group
Group type: EXPERIMENTAL
Intervention: Efinaconazole 10% solution
Number of subjects: 0
Study 25007364 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 25007707 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician Engagement scale
Number of subjects: 4266
Study 25007707 — intervention group
Group type: EXPERIMENTAL
Intervention: Teamness scale
Number of subjects: 4266
Study 25007707 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Effectiveness scale
Number of subjects: 4266
Study 25007944 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg/day for 6 months
Number of subjects: 30
Study 25008852 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels across different latitudes
Number of subjects: 2500
Study 25008852 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D (25(OH)D) levels in Ghana
Number of subjects: 2500
Study 25008855 — intervention group
Group type: EXPERIMENTAL
Intervention: Good financial planning skills and low delay discounting
Number of subjects: 975
Study 25008855 — intervention group
Group type: EXPERIMENTAL
Intervention: Good financial planning skills and high delay discounting
Number of subjects: 975
Study 25008855 — intervention group
Group type: EXPERIMENTAL
Intervention: High food insecurity with good financial planning skills and low delay discounting
Number of subjects: 975
Study 25008855 — intervention group
Group type: EXPERIMENTAL
Intervention: High food insecurity with good financial planning skills and high delay discounting
Number of subjects: 975
Study 25008856 — intervention group
Group type: EXPERIMENTAL
Intervention: Provided diet containing 6-cup equivalents (1046 g/d) of vegetables and fruit (8 wk, phase 2)
Number of subjects: 29
Study 25008856 — intervention group
Group type: COMPARATOR
Intervention: Low-carotenoid diets (6 wk, phases 1 and 3)
Number of subjects: 29
Study 25008856 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (final 8 wk, phase 4)
Number of subjects: 29
Study 25008856 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin carotenoid status assessed by resonance Raman spectroscopy
Number of subjects: 29
Study 25008856 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin and plasma carotenoid values correlation
Number of subjects: 29
Study 25008917 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 gp140 linked to HSP70 administered vaginally
Number of subjects: 0
Study 25009010 — intervention group
Group type: EXPERIMENTAL
Intervention: AKT inhibitor treatment during the fourth line of therapy
Number of subjects: 1
Study 25009013 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with cetuximab, paclitaxel, and carboplatin
Number of subjects: 63
Study 25009013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (CRT) with cetuximab, paclitaxel, and carboplatin
Number of subjects: 63
Study 25009013 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with cetuximab, paclitaxel, and carboplatin followed by CRT
Number of subjects: 63
Study 25009225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 25009371 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin dialysis
Number of subjects: 0
Study 25009371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies with albumin dialysis
Number of subjects: 0
Study 25010170 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study 25010745 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium at 2.5 mmol/l
Number of subjects: 20
Study 25010745 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium at 1 mmol/l
Number of subjects: 20
Study 25010745 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 20
Study 25010745 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 20
Study 25010745 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 20
Study 25011615 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin zeta (median dose 30,000 IU/week)
Number of subjects: 2333
Study 25011656 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg linezolid intravenously twice a day
Number of subjects: 30
Study 25011943 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (40% more than baseline requirement for 8 weeks)
Number of subjects: 29
Study 25011951 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycation of the α-chain (Glα) in neonates from GDM
Number of subjects: 67
Study 25011951 — intervention group
Group type: COMPARATOR
Intervention: Glycation of the α-chain (Glα) in neonates from NGT
Number of subjects: 67
Study 25011951 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Glα with maternal A1C in overall cohort
Number of subjects: 67
Study 25011951 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Glα with maternal A1C in GDM group
Number of subjects: 67
Study 25011951 — intervention group
Group type: COMPARATOR
Intervention: Correlation of Glα with maternal A1C in NGT group
Number of subjects: 67
Study 25012414 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Assessment of Cognition in Affective Disorder (BAC-A)
Number of subjects: 432
Study 25012414 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective Processing Test
Number of subjects: 432
Study 25012414 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite score combining six core cognitive subtests of BAC-A and two measures from the Affective Processing Test
Number of subjects: 432
Study 25012414 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cognitive tests
Number of subjects: 432
Study 25012414 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective Processing Test measures
Number of subjects: 432
Study 25012943 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Number of subjects: 12
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian smokers
Number of subjects: 1672
Study 25012994 — intervention group
Group type: COMPARATOR
Intervention: African American smokers
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Female smokers
Number of subjects: 1672
Study 25012994 — intervention group
Group type: COMPARATOR
Intervention: Male smokers
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth control pill users (females)
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy users (females)
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette consumption
Number of subjects: 1672
Study 25012994 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentholated cigarette users
Number of subjects: 1672
Study 25013718 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial monitoring of IL-6 and CRP levels using a bedside micro sample test device
Number of subjects: 0
Study 25013718 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent biomarker monitoring
Number of subjects: 0
Study 25013998 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (300-1200 mg) administered once daily
Number of subjects: 43
Study 25015089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m²) single-dose 2-3 hours before surgery
Number of subjects: 12
Study 25015089 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) daily for 2-5 doses, last dose 2-3 hours before surgery
Number of subjects: 12
Study 25015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and education
Number of subjects: 100
Study 25015177 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100
Study 25015177 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 100
Study 25015202 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation with weekly paclitaxel (60 mg/m² administered once weekly for 5 weeks during radiation therapy)
Number of subjects: 57
Study 25015413 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g oral glucose tolerance test (OGTT) using IADPSG criteria
Number of subjects: 2563
Study 25015413 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose challenge test (GCT)
Number of subjects: 2563
Study 25015413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized routine care protocol for diabetes and GDM treatment
Number of subjects: 2563
Study 25015575 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepato-portoenterostomy (HPE) surgery
Number of subjects: 219
Study 25015938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, and prednisone
Number of subjects: 0
Study 25015938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib, melphalan, prednisone, and thalidomide
Number of subjects: 0
Study 25015938 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib and thalidomide maintenance
Number of subjects: 0
Study 25016003 — intervention group
Group type: EXPERIMENTAL
Intervention: Imexon (1000 mg/m² IV daily for 5 days in 21-day cycles)
Number of subjects: 22
Study 25016003 — intervention group
Group type: EXPERIMENTAL
Intervention: Imexon
Number of subjects: 22
Study 25016127 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hematin
Number of subjects: 108
Study 25016368 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive Sleep Apnea (OSA) treatment according to national guidelines
Number of subjects: 350
Study 25016368 — intervention group
Group type: COMPARATOR
Intervention: Non-OSA subjects
Number of subjects: 350
Study 25016482 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg daily)
Number of subjects: 17
Study 25016924 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (8 mg/kg intravenously every 2 weeks)
Number of subjects: 60
Study 25018070 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe asthma
Number of subjects: 38
Study 25018070 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects (including severe asthma, mild-to-moderate asthma, and normals)
Number of subjects: 38
Study 25018070 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WA%, race, and health care utilization
Number of subjects: 38
Study 25018648 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 412
Study 25018648 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 412
Study 25018648 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/day
Number of subjects: 412
Study 25018648 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 412
Study 25018648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 412
Study 25018650 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine-based multimodal analgesia
Number of subjects: 191
Study 25018650 — intervention group
Group type: COMPARATOR
Intervention: IV opioid PCA
Number of subjects: 191
Study 25018910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived, culture-expanded allogeneic mesenchymal stem cells administered into the suprarenal aorta after reflow.
Number of subjects: 0
Study 25018910 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated controls
Number of subjects: 0
Study 25019562 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial scar group
Number of subjects: 429
Study 25019562 — intervention group
Group type: COMPARATOR
Intervention: T1 time 12 minutes after contrast material injection
Number of subjects: 429
Study 25019562 — intervention group
Group type: COMPARATOR
Intervention: T1 time 25 minutes after contrast material injection
Number of subjects: 429
Study 25019647 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 7248
Study 25019647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7248
Study 25020262 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite in a continual infusion of 750μg/24h for 6 days
Number of subjects: 65
Study 25020262 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 25022285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5-20 mg/day
Number of subjects: 43
Study 25022447 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum Induction (SI)
Number of subjects: 555
Study 25022447 — intervention group
Group type: EXPERIMENTAL
Intervention: Early morning expectorated sputum
Number of subjects: 555
Study 25022596 — intervention group
Group type: EXPERIMENTAL
Intervention: ART (tenofovir/emtricitabine/efavirenz, with ritonavir/lopinavir substitution for efavirenz available)
Number of subjects: 197
Study 25022828 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg (Clop-75)
Number of subjects: 72
Study 25022828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg (Pras-5)
Number of subjects: 72
Study 25022828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg (Pras-10)
Number of subjects: 72
Study 25022839 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft
Number of subjects: 35
Study 25022839 — intervention group
Group type: COMPARATOR
Intervention: Autograft
Number of subjects: 35
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omentin-1 levels in AMI patients at baseline: 18.73 ± 3.66 ng/ml
Number of subjects: 78
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hsCRP) levels in AMI patients at baseline
Number of subjects: 78
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-18 (IL-18) levels in AMI patients at baseline
Number of subjects: 78
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: White blood cells count (WBC) in AMI patients at baseline
Number of subjects: 78
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemerin levels in AMI patients at baseline: 263.37 ± 73.32 ng/ml
Number of subjects: 78
Study 25022935 — intervention group
Group type: EXPERIMENTAL
Intervention: Ejection fraction in AMI patients at baseline
Number of subjects: 78
Study 25022935 — intervention group
Group type: COMPARATOR
Intervention: Comparison of AMI patients with healthy controls
Number of subjects: 78
Study 25023004 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute ischaemic atherothrombotic stroke (IAS)
Number of subjects: 100
Study 25023004 — intervention group
Group type: COMPARATOR
Intervention: Acute coronary syndromes (ACS)
Number of subjects: 100
Study 25023004 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid distensibility
Number of subjects: 100
Study 25023199 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention-to-treat principles reinforced by vigilant senior investigators during trial conduct
Number of subjects: 0
Study 25023199 — intervention group
Group type: COMPARATOR
Intervention: Lack of understanding of intention-to-treat principles by trial personnel
Number of subjects: 0
Study 25023626 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR (multimarker assay)
Number of subjects: 271
Study 25023626 — intervention group
Group type: COMPARATOR
Intervention: ICC (immunocytochemistry)
Number of subjects: 271
Study 25023626 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR (KRT19 marker)
Number of subjects: 271
Study 25023626 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR (TWIST1 marker)
Number of subjects: 271
Study 25023626 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR (hMAM marker)
Number of subjects: 271
Study 25023626 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordance between RT-qPCR and ICC
Number of subjects: 271
Study 25023888 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (50 μg/kg; i.p.)
Number of subjects: 0
Study 25023888 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (10 mg/kg; i.p.)
Number of subjects: 0
Study 25023888 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (50 μg/kg; i.p., daily for 3 weeks)
Number of subjects: 0
Study 25023888 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine (0.5 mg/kg; p.o. for 8-9 weeks)
Number of subjects: 0
Study 25023926 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Portfolio Diet (MPD)
Number of subjects: 30
Study 25023926 — intervention group
Group type: COMPARATOR
Intervention: Time controls (no diet therapy)
Number of subjects: 30
Study 25024076 — intervention group
Group type: EXPERIMENTAL
Intervention: RVD induction (lenalidomide, bortezomib, dexamethasone) followed by transplantation and RVD consolidation
Number of subjects: 31
Study 25024303 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, cyclophosphamide with vincristine, prednisone, and rituximab)
Number of subjects: 24
Study 25025522 — intervention group
Group type: EXPERIMENTAL
Intervention: Social marketing program
Number of subjects: 7101
Study 25025522 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 7101
Study 25025611 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing prognostic models for the Glasgow Outcome Scale Extended (GOS-E) at 6 months after injury (based on CRASH study data and Nijmegen data)
Number of subjects: 386